David R. Minor - Researcher Profile | RDL Research Database

Publications

2 shown

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow , Jason Chesney , Anna C. Pavlick +18 more

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...

2015 New England Journal of Medicine 2716 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 5,333
Institution: Northern California Melanoma Center

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-2186-2016

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.